RPL17 and colonic neoplasm: In a study of neoadjuvant immunotherapy (nivolumab [anti-PD-1] plus ipilimumab [anti-CTLA-4]) for stage I-III colon cancer patients, CD8+PD-1+ T-cell infiltration was a predictive biomarker of response in pMMR patients (97).